Previous announcements have indicated that if the trial results are showing overwhelming efficacy the treatment will be granted approval as per FDA guide lines.
So at 45% with the expected announcement early November there is a chance the trial could be granted approval by the FDA.
Alot of people will be able to recover instead of dying or being on a MECHANICAL VENTALATOR for an extended period which has lasting consequences.
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment, page-334
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
0.035(3.40%) |
Mkt cap ! $1.230B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.09 | $1.03 | $3.977M | 3.727M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 37580 | $1.06 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 13222 | 11 |
View Market Depth
| Last trade - 12.45pm 02/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |